Back to top anchor

IMPEDE-PKD: Metformin to protect kidney function in polycystic kidney disease

Year:
2023
Duration:
66 months
Approved budget:
$1,439,999.74
Researchers:
Professor Dr Suetonia Green
,
Professor Andrew Mallett
,
Dr Luke Wilson
,
Professor David Johnson
,
Associate Professor Rachael Walker
,
Dr Michael Collins
,
Dr Adam Mullan
,
Ms Jasjot Maggo
,
Dr Gabor Mihala
Host:
University of Otago
Health issue:
Renal and urogenital
Proposal type:
Project
Lay summary
IMPEDE-PKD is a clinical trial evaluating whether metformin prevents kidney failure in people with polycystic kidney disease (PKD). PKD is a genetic condition causing large kidney cysts. Affected people often require dialysis or a kidney transplant and can experience pain and disfigurement. There is no targeted treatment to prevent cyst growth for patients in Aotearoa/New Zealand. The IMPEDE-PKD trial will involve 100 patients in New Zealand with PKD and decreased kidney function. Patients will receive either metformin or a matching placebo (inactive pill) for 2 years. We will evaluate whether metformin slows kidney failure after two years of treatment. Whanau Māori will be partnered with a navigator Māori to provide culturally specific support while participating in IMPEDE-PKD.